Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

revenues were due to payments received in previous years from NicOx' partnered programs with Merck & Co., Inc. in the antihypertensive field and Pfizer Inc in ophthalmology.

Operating expenses totaled EUR86.4 million in 2008, compared to EUR61.8 million in 2007. The majority of these expenses were associated with the phase 3 clinical program for naproxcinod in osteoarthritis (OA) patients, which was successfully completed in the second half of 2008. Naproxcinod is the first Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) and a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) is projected for mid-2009. NicOx' net loss was EUR73.9 million for the full year 2008, compared to EUR32.1 million in 2007.

On December 31, 2008, NicOx had cash, cash equivalents and financial instruments of EUR104.7 million, compared to EUR172.8 million on December 31, 2007.

Considerable progress made in naproxcinod pre-commercialization activities

In 2008, NicOx signed two major manufacturing agreements to prepare the commercial launch of naproxcinod. In September, an agreement was signed with Capsugel, for the commercial manufacture and supply of naproxcinod capsules and in December, an agreement was signed with DSM for the commercial manufacturing and supply of naproxcinod drug substance (Active Pharmaceutical Ingredient, API). The aim of these agreements is to ensure sufficient commercial supplies of naproxcinod to underpin its successful market launch.

NicOx is currently in discussions with a number of companies regarding a potential commercialization agreement for naproxcinod. NicOx aims to retain certain commercialization rights for naproxcinod, in order to fully exploit the drug's commercial and strategic value and aid the Company's planned transition to a self-sustainable pharmaceutical business.

Completed phase 3 program confirms naprox
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... Knowledgent , the data and analytics firm, today announced a new ... the healthcare industry. , As the Internet of Things (IoT) continues to grab headlines ... years as more entities become technology enabled through Electronic Medical Records (EMRs). , With ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Business Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business ... of iLab’s suite of tools. This entails not only introducing iLab to potential ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research ... California Los Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer ... the world’s first multidisciplinary Open Access journal. , Christopher Ryan PhD, of ...
(Date:9/1/2015)... 2015 Shire plc (LSE: SHP, NASDAQ: ... to its Board of Directors as a Non-Executive Director. ... & Risk Committee of the Shire Board. Both appointments will ... previously served as Chairman, President and Chief Executive Officer of ... her 12-year tenure at D&B, she helped drive the transformation ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2
... Date: May 10, 2011 ... technology, media, telecommunications, life sciences, and clean technology companies in North ... What:   Nominations are now being accepted. Companies ... 2006 to 2010.  To be eligible for Deloitte,s Technology Fast 500 ...
... Brainlab has received 510(k) clearance from the U.S. ... radiosurgery planning solution. This innovative software package will ... existing Linac (linear accelerator) radiosurgery hardware and offer ... the need for costly hardware upgrades. ...
... The Laboratory Department for Probiotics Research at the ... YAMASHIRO Yuichiro et al.) studied supplementation of probiotic ... in elderly individuals living at a nursing home ... gastroenteritis. Analysis of fecal flora ...
Cached Biology Technology:Deloitte Seeks Nominations for 2011 Technology Fast 500™ Ranking 2Brainlab Announces FDA 510(k) Clearance for New HybridArc™ Software for Radiosurgery 2Brainlab Announces FDA 510(k) Clearance for New HybridArc™ Software for Radiosurgery 3Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection 2Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection 3
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/24/2015)... -- Based on its recent analysis of the biometric products market, ... Company of the Year Award. DERMALOG is the leading German ... Africa . It has particularly gained prominence in ... of the largest biometric mass applications in the world, and ... of Nigeria with its biometric products. ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... rice cultivation built in the middle basin of the Guadiana ... migratory dabbling duck species to significantly increase in number during ... Vegas Altas del Guadiana is turned into a new Special ... are in decline and the loss of natural wetland is ...
... tend to think of ozone as something in the ... radiation. At the ground level, however, ozone is a ... a University of Illinois associate professor of crop sciences ... that establishing the exposure threshold for damage is critical ...
... tarantulas are known from a few tropical places in ... tarantulas generally have a lighter build, thinner bodies and longer ... area at the ends of their legs, allowing them to ... more agile. Their core area is the Amazon, from ...
Cached Biology News:Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 39 colorful and endangered tree-dwelling tarantulas discovered in Brazil 2
... mir Vana miRNA Bioarray Essentials Kit provides all ... post-hybridization washing of the mir Vana miRNA ... been labeled using Ambions mir Vana miRNA ... control miRNA (Bioarray ID BA10001) that should be ...
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
Biology Products: